Select criteria to filter your search results
Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - QUANTUM GENOMICS : Looking Beyond Firibastat's rHTN program - BUY, TP 9,0€

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - GRIFOLS : Redressement de la marge brute, OPEX très élevées - NEUTRE, OC 24€

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - DIASORIN : Dans l'attente du CMD du 10 juin - NEUTRE, OC 78€ (vs 77€)

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - QIAGEN : Guidance réitérée avec un S2 plus dynamique - NEUTRE, OC 36€ (vs 37€)

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - SPINEWAY : Visibilité encore limitée - NEUTRE, OC 0,14€ (vs 0,22€)

Matthieu Lavillunière ...
  • Maxime Dubreil
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - AKKA : Un T1 tout à fait en ligne - NEUTRE, OC 65€ (vs 66€)

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - ORYZON GENOMICS : Vafidemstat shows promise in BPD and ADHD - BUY, TP €8,8

Johann Carrier ...
  • Olga Smolentseva
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - NOVACYT : De fortes attentes sur 2019 liées au recentrage - ACHAT, OC 0,68€ (vs 0,80€)

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - TRANSGENE : Nouvel accord de collaboration validant Invir-IO - ACHAT, OC 4,2€ (vs 4,0€)

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - NOXXON PHARMA : Le glioblastome en renfort - ACHAT, OC 2,8€ (vs 4,9€)

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - BIOMERIEUX : Faux départ au T1, objectifs 2019 réitérés - VENTE, OC 59€ (vs 57€)

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - NEOVACS : Can IFNα-Kinoid change clinical endpoints in SLE ? - NEUTRE, OC 0,29€

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - ISO IMMUNOTHERAPEUTICS : BiCKI to expand immuno-oncology pipeline - BUY, PT €8,7

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - OSE IMMUNOTHERAPEUTICS : BiCKI to expand immuno-oncology pipeline - BUY, PT €8,7

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - BIOPHYTIS : Sarconeos advances in Sarcopenia and DMD - BUY, PT €4,4 (vs €6)

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - BIOPHYTIS : Sarconeos advances in Sarcopenia and DMD - BUY, PT €4,4 (vs €6)

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - CROSSJECT : Capitaliser sur la crise des opiacées aux US - ACHAT, OC 2,9€ (vs 2,1€)

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - VALBIOTIS: Valedia et le virage préventif du diabète de type 2

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - THERACLION : Les varices, un relais de croissance essentiel - ACHAT, OC 1,3€ (vs 3,6€)

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - SPINEWAY : Des objectifs 2021 ambitieux mais crédibles - NEUTRE, OC 0,22€ (vs 0,21€)

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch